AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses at week 14, with 69% of patients achieving low disease activity.